Immunohistochemical study of VEGF expression in oral squamous cell carcinomas: Correlation with the mTOR-HIF-1α tathway

Anticancer Research

Volumn 31, Issue 12, 2011, Pages 4429-4437

  Naruse, Tomofumi ^a   Kawasaki, Goro ^a   Yanamoto, Souichi ^a   Mizuno, Akio ^a   Umeda, Masahiro ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Angiogenesis; HIF 1 ; mTOR; Oral cancer; VEGF

Indexed keywords

FORMALDEHYDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; PARAFFIN; VASCULOTROPIN A; VASCULOTROPIN C;

AGE; AGED; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; MOUTH MUCOSA; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TISSUE FIXATION;

CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MOUTH NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84855172659     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Mao L, Hong WK and Papadimitrakopoulou VA: Focus on head and neck cancer. Cancer Cell 5: 311-316, 2004. (Pubitemid 38482067)
2. Peter C and Rakesh KJ: Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
3. Zetter BR: Angiogenesis and tumor metastasis. Annu Rev Med 49: 407-24, 1998.
4. Carmeliet P: Angiogenesis in health and disease. Nat Med 6: 653-660, 2003.
5. Risau W: Mechanisums of angiogenesis. Nature 386: 671-674, 1997.
6. Otrock ZK, Makarem JA and Shamseddine AI: Vascular endothelial growth factor family ligands and receptors: review. Blood Cells Mol Dis 38: 258-268, 2007. (Pubitemid 46518176)
7. Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature 438: 967-974, 2005. (Pubitemid 43093963)
8. Pouysségur J, Dayan F and Mazure NM: Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441: 437-443, 2006. (Pubitemid 44050138)
9. Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signaling controls tumour cell growth. Nature 441: 424-430, 2006. (Pubitemid 44050136)
10. Dorević G, Matusan-Ilijas K, Babarović E, Hadzisejdić I, Grahovac M, Grahovac B and Jonjić N: Hypoxia-inducible factor-1alpha correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma. J Exp Clin Cancer Res 28: 40, 2009.
11. Carrillo de Santa Pau E, Arias FC, Caso PE, Muñoz MGM, Sánchez HI, Muguruza TI, Moreno BR, Sacristán LS, Gómez PA and del Val Toledo LM: Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with non-small cell lung cancer. Cancer 115: 1701-1712, 2009.
12. Kyzas PA, Cunha IW and Ioannidis JP: Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res 11: 1434-1440, 2005. (Pubitemid 40315223)
13. Cao D, Hou M, Guan YS, Jiang M, Yang Y and Gou HF: Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC Cancer 9: 432-440, 2009.
14. Lee SJ, Kim JG, Sohn SK, Chae YS, Moon JH, Kim SN, Bae HI, Chung HY and Yu W: No association of vascular endothelial growth factor-A (VEGF-A) and VEGF-C expression with survival in patients with gastric cancer. Cancer Res Treat 41: 218-223. 2009.
15. Ding MX, Lin XQ, Fu XY, Zhang N and Li JC: Expression of vascular endothelial growth factor-C and angiogenesis in esophageal squamous cell carcinoma. World J Gastroenterol 12: 4582-4585, 2006. (Pubitemid 44256352)
16. Beasley NJ, Prevo R, Banerji S, Leek RD, Moore J, van Trappen P, Cox G, Harris AL and Jackson DG: Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res 62: 1315-1320, 2002. (Pubitemid 34407785)
17. Duncan TJ, Al-Attar A, Rolland P, Scott IV, Deen S, Liu DT, Spendlove I and Durrant LG: Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res 14: 3030-3035, 2008.
18. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004. (Pubitemid 38702844)
19. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douilard JY, Lathia C, Schwartz B, Taylor I, Moscovici M and Salth LB: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 4293-4300, 2006. (Pubitemid 46630787)
20. Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, Booth BP, Verbois SL, Morse DE, Liang CY, Chidambaram N, Jiang JX, Tang S, Mahjoob K, Justice R and Pazdur R: Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 13: 1367-1373, 2007. (Pubitemid 46450424)
21. Daponte A, Ioannou M, Mylonis I, Simos G, Minas M, Messinis IE and Koukoulis G: Prognostic significance of hypoxia-inducible factor 1 alpha (HIF-1alpha) expression in serous ovarian cancer: an immunohistochemical study. BMC Cancer 8: 335-344, 2008.
22. Beasley NJ, Leek R, Alam M, Turley H, Cox GJ, Gatter K, Millard P, Fuggle S and Harris AL: Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 62: 2493-2497, 2002. (Pubitemid 34462724)
23. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jalesz R, Kubista E, Birner P and Oberhuber G: Austrian Breast and Colorectal Cancer Study Group: Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8: 1831-1837, 2002. (Pubitemid 34633742)
24. Kurokawa T, Miyamoto M, Kato K, Cho Y, Kawarada Y, Hida Y, Shinohara T, Itoh T, Okushiba S, Kondo S and Katoh H: Overexpression of hypoxia-inducible factor 1alpha (HIF-1alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br J Cancer 89: 1042-1047, 2003. (Pubitemid 37239209)
25. Oh SY, Kwon HC, Kim SH, Jang JS, Kim MC, Kim KH, Han JY, Kim CO, Kim SJ, Jeong JS and Kim HJ: Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer. BMC Cancer 8: 123-129, 2008.
26. Sobin LH and Wittekind CH: International Union Against Cancer: TNM Classification of Malignant Tumours, 5th edn., New York, Wiley, pp. 1-227, 1997.
27. Wahi PN: (WHO) Histological Typing of Oral and Oropharyngeal Tumours, International Histological Classification of Tumours, 4th edn. Geneva, WHO, pp. 1-28, 1971.
28. Yamamoto E, Kohama G, Sunakawa H, Iwai M and Hiratsuka H: Mode of invasion, bleomycin sensitivity, and clinical course in squamous cell carcinoma of the oral cavity. Cancer 51: 2175-80, 1983. (Pubitemid 13106840)
29. Yanamoto S, Kawasaki G, Yoshitomi I, Iwamoto T, Hirata K and Mizuno A: Clinicopathologic significance of EpCAM expression in squamous cell carcinoma of the tongue and its possibility as a potential target for tongue cancer gene therapy. Oral Oncol 43: 869-877, 2007. (Pubitemid 47369249)
30. Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, Jia Z, Li Q, Yao JC and Xie K: Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer. Clin Cancer Res 15: 1821-1829, 2009.
31. Dobashi Y, Suzuki S, Matsubara H, Kimura M, Endo S and Ooi A: Critical and diverse involvement of AKT/mammalian target of rapamycin signaling in human lung carcinomas. Cancer 115: 107-118, 2009.
32. Faried LS, Faried A, Kanuma T, Aoki H, Sano T, Nakazato T, Tamura T, Kuwano H and Minegishi T: Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy. Mol Carcinog 47: 446-457, 2008. (Pubitemid 351822303)
33. Pelloski CE, Lin E, Zhang L, Yung WK, Colman H, Liu JL, Woo SY, Heimberger AB, Suki D, Prados M, Chang S, Barker FG 3rd, Fuller GN and Aldape KD: Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 12: 3935-3941, 2006. (Pubitemid 44078078)
34. Miyazawa M, Yasuda M, Fujita M, Kajiwara H, Hirabayashi K, Takekoshi S, Hirasawa T, Murakami M, Ogane N, Kiguchi K, Ishiwata I, Mikami M and Osamura RY: Therapeutic strategy targeting the mTOR-HIF-1α-VEGF pathway in ovarian clear cell adenocarcinoma. Pathol Int 59: 19-27, 2009.
35. Stefansson IM, Salvesen HB and Akslen LA: Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res 66: 3303-3309, 2006.
36. Uchida S, Shimada Y, Watanabe G, Tanaka H, Shibagaki I, Miyahara T, Ishigami S and Imamura M: In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br J Cancer 77: 1704-1709, 1998. (Pubitemid 28230478)
37. Miyazawa M, Yasuda M, Fujita M, Hirabayashi K, Hirasawa T, Kajiwara H, Muramatsu T, Miyazaki S, Harasawa M, Matsui N, Ogane N, Murakami M, Mikami M, Yanase T and Osamura RY: Granulosa cell tumor with activated mTOR-HIF-1alpha-VEGF pathway. J Obstet Gynaecol Res 36: 448-453, 2010.
38. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G and Milella M: Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66: 5549-5554, 2006. (Pubitemid 43927103)